Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03396042 · ClinicalTrials.gov registry record
Natural History Study of CEP290-Related Retinal Degeneration
A clinical trial of Eye Diseases and Retinal Disease, sponsored by Editas Medicine.
- Completed
- Registry status
- 26
- Enrollment target
- 7
- Study locations
NCT03396042 is a study of Eye Diseases and Retinal Disease that has completed, run by Editas Medicine. The registered enrollment target is 26 participants, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT03396042, a study of Eye Diseases and Retinal Disease, has completed, sponsored by Editas Medicine.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
- 7
- Study locations
Study Summary
A prospective natural history study with systematic assessments and uniform follow-up to provide a high-quality dataset for assisting in the design of future clinical treatment trials involving patients with CEP290-related retinal degeneration caused by the common intron 26 mutation.
Conditions Studied
Study Locations (7)
Other
- Universite Pierre et Marie Curie - Paris
- Universitaetsklinikum Giessen and Marburg GmbH - Giessen
Florida
- Bascom Palmer Eye Institute - Miami
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Michigan
- W.K. Kellogg Eye Center - Ann Arbor
Oregon
- Casey Eye Institute - OHSU - Portland
Gelderland
- Radboud Universitair Medisch Centrum - Nijmegen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-12-17 |
| Est. Completion | 2022-05-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03396042
The ClinicalTrials.gov registry entry for NCT03396042 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Editas Medicine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Eye Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT03396042 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03396042 about?
NCT03396042 is a clinical study titled "Natural History Study of CEP290-Related Retinal Degeneration". A prospective natural history study with systematic assessments and uniform follow-up to provide a high-quality dataset for assisting in the design of future clinical treatment trials involving patients with CEP290-related retinal degeneration caused by the common intron 26 mutation.
What is the current status of trial NCT03396042?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2017-12-17. Estimated completion is 2022-05-06.
What conditions does trial NCT03396042 study?
This clinical trial studies the following conditions: Eye Diseases, Retinal Disease, Retinal Degeneration, Eye Diseases, Hereditary, Blindness.
Who is sponsoring clinical trial NCT03396042?
This trial is sponsored by Editas Medicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03396042 being conducted?
This trial has 7 study locations across Florida, Massachusetts, Michigan, Oregon, Gelderland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptive Optics Retinal Imaging
RECRUITING
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
RECRUITING · NA
-
IRIS Registry: Intelligent Research in Sight Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.